Interferon-β mechanisms of action in multiple sclerosis
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) is a chronic autoimmune disease of the CNS characterized by inflammation, demyelination, and axonal injury. These pathologic effects are manifested in clinical symptoms of relapse and disability. Various disease-modifying therapies have been developed in recent years to modulate the body's immune response. Among the most widely used are the beta interferons (IFNbeta). All produce comparable biological effects and are approved for the treatment of relapsing-remitting MS (RRMS). Although the precise mechanisms through which IFNbeta achieves its antiinflammatory and immunomodulatory effects remain uncertain, several modes of action have been proposed, including inhibition of T-cell activation and proliferation; apoptosis of autoreactive T cells; induction of regulatory T cells; inhibition of leukocyte migration across the blood-brain barrier; cytokine modulation; and potential antiviral activity. Endogenously produced IFNbeta in the injured brain is also now believed to contribute to mediation of antiinflammatory and regenerative effects. All these mechanisms are believed to underlie the therapeutic effect of IFNbeta in the treatment of RRMS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Delves, P. J., & Roitt, I. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007063430107 · Cited by 1,666
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
Tzartos, J. S., Friese, M. A., Craner, M. J., Palace, J., Newcombe, J., Esiri, M. M., & Fugger, L. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070690 · Cited by 1,187
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,053
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) · Neurology · doi:10.1212/wnl.45.7.1277 · Cited by 916
Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome
Groom, J., Kalled, S. L., Cutler, A. H., Olson, C., Woodcock, S. A., Schneider, P., Tschopp, J., Cachero, T. G., Batten, M., Wheway, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214121 · Cited by 712
Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease
Zhang, Y., Schuff, N., Jahng, G. H., Bayne, W., Mori, S., Schad, L., Mueller, S., Du, A. T., Kramer, J. H., Yaffe, K., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000250326.77323.01 · Cited by 512
Stohl, W., Metyas, S., Tan, S., Cheema, G. S., Oamar, B., Xu, D., Roschke, V., Wu, Y., Baker, K. P., & Hilbert, D. M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11354 · Cited by 503
Krumbholz, M., Theil, D., Derfuss, T., Rosenwald, A., Schrader, F., Monoranu, C.-M., Kalled, S. L., Hess, D. M., Serafini, B., Aloisi, F., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041674 · Cited by 492
Delves, P. J., & Roitt, I. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007133430207 · Cited by 468
The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice
Guo, B., Chang, E. Y., & Cheng, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33342 · Cited by 371
Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis
Waubant, E., Goodkin, D. E., Gee, L., Bacchetti, P., Sloan, R., Stewart, T., Andersson, P.-B., Stabler, G., & Miller, K. (1999) · Neurology · doi:10.1212/wnl.53.7.1397 · Cited by 234
Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.
Genç, K., Dona, D. L., & Reder, A. T. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119455 · Cited by 228
Tan, S., Xu, D., Roschke, V., Perry, J. W., Arkfeld, D. G., Ehresmann, G. R., Migone, T., Hilbert, D. M., & Stohl, W. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10860 · Cited by 206
Site-specific mutagenesis of the human fibroblast interferon gene.
Mark, D. F., Lu, S. D., Creasey, A. A., Yamamoto, R., & Lin, L. S. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.18.5662 · Cited by 197
Cadavid, D., Wolansky, L. J., Skurnick, J., Lincoln, J., Cheriyan, J., Szczepanowski, K., Kamin, S. S., Pachner, A. R., Halper, J., & Cook, S. D. (2009) · Neurology · doi:10.1212/01.wnl.0000345970.73354.17 · Cited by 185
Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis
Dhib-Jalbut, S. (2002) · Neurology · doi:10.1212/wnl.58.8_suppl_4.s3 · Cited by 184
Self-citationInterferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity
Krumbholz, M., Faber, H., Steinmeyer, F., Hoffmann, L.-A., Kümpfel, T., Pellkofer, H., Derfuss, T., Ionescu, C., Starck, M., Hafner, C., et al. (2008) · Brain · doi:10.1093/brain/awn077 · Cited by 165
Interferon-beta: Mechanism of action and dosing issues
Markowitz, C. E. (2007) · Neurology · doi:10.1212/01.wnl.0000277703.74115.d2 · Cited by 163
Changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS
Trojano, M., Avolio, C., Liuzzi, G. M., Ruggieri, M., Defazio, G., Liguori, M., Santacroce, M. P., Paolicelli, D., Giuliani, F., Riccio, P., et al. (1999) · Neurology · doi:10.1212/wnl.53.7.1402 · Cited by 139
The role of BAFF in immune function and implications for autoimmunity
Kalled, S. L. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00219.x · Cited by 133
Wang, X., Chen, M., Wandinger, K.-P., Williams, G. J., & Dhib-Jalbut, S. S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.1.548 · Cited by 116
Self-citationInterferon β-lb reduces Interferon γ-induced antigen-presenting capacity of human glial and B cells
Jiang, H., Milo, R., Swoveland, P., Johnson, K. P., Panitch, H., & Dhib-Jalbut, S. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(95)00072-a · Cited by 97
Self-citationPathogenesis of myelin/oligodendrocyte damage in multiple sclerosis
Dhib-Jalbut, S. (2007) · Neurology · doi:10.1212/01.wnl.0000275228.13012.7b · Cited by 95
Self-citationInterferon‐β Is a Potent Promoter of Nerve Growth Factor Production by Astrocytes
Boutros, T., Croze, E., & Yong, V. W. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69030939.x · Cited by 93
Interferon Beta Promotes Nerve Growth Factor Secretion Early in the Course of Multiple Sclerosis
Biernacki, K., Antel, J. P., Blain, M., Narayanan, S., Arnold, D. L., & Prat, A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.4.563 · Cited by 92
Özenci, V., Kouwenhoven, M. C. M., Teleshova, N., Pashenkov, M. V., Fredrikson, S., & Link, H. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00281-2 · Cited by 87
Differential diagnosis and evaluation in pediatric multiple sclerosis
Hahn, J. S., Pohl, D., Rensel, M. R., & Rao, S. D. (2007) · Neurology · doi:10.1212/01.wnl.0000259403.31527.ef · Cited by 74
Multiple Cerebral Microbleeds: Mri Marker of a Diffuse Hemorrhage–Prone State
Chalela, J. A., Kang, D., & Warach, S. J. (2004) · Journal of Neuroimaging · doi:10.1111/j.1552-6569.2004.tb00216.x · Cited by 73
Saresella, M., Marventano, I., Longhi, R., Lissoni, F., Trabattoni, D., Mendozzi, L., Caputo, D., & Clerici, M. (2008) · The FASEB Journal · doi:10.1096/fj.08-110650 · Cited by 72
Graber, J. J., Ford, D., Zhan, M., Francis, G., PANITCH, H. S., & Dhib-Jalbut, S. S. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.01.011 · Cited by 70
Self-citationProtective autoimmunity in the nervous system
Graber, J. J., & Dhib-Jalbut, S. S. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.001 · Cited by 69
Self-citationInterferon-β is neuroprotective against the toxicity induced by activated microglia
Jin, S., Kawanokuchi, J., Mizuno, T., Wang, J., Sonobe, Y., Takeuchi, H., & Suzumura, A. (2007) · Brain Research · doi:10.1016/j.brainres.2007.08.055 · Cited by 62
Teleshova, Бао, Kivisäkk, Özenci, V., Mustafa, & Link (2000) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2000.00688.x · Cited by 61
Caggiula, M., Batocchi, A. P., Frisullo, G., Angelucci, F., Patanella, A. K., Sancricca, C., Nociti, V., Tonali, P. A., & Massimiliano Mirabella, A. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.09.005 · Cited by 60
Impact of Disease-Modifying Therapies on Brain and Spinal Cord Atrophy in Multiple Sclerosis
Rudick, R. A. (2004) · Journal of Neuroimaging · doi:10.1177/1051228404266269 · Cited by 48
Stem cell based delivery of IFN-β reduces relapses in experimental autoimmune encephalomyelitis
Makar, T. K., Trisler, D. N., Bever, C. T., Goolsby, J. E., Sura, K. T., Balasubramanian, S., Sultana, S., Patel, N. C., Ford, D., Singh, I. S., et al. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.02.014 · Cited by 47
Self-citationAntonetti, F., Finocchiaro, O., Mascia, M., Terlizzese, M., & Jaber, A. (2002) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900260475696 · Cited by 47
Graber, J. J., Zhan, M., Ford, D., Kursch, F., Francis, G., Bever, C. T., PANITCH, H. S., Calabresi, P. A., & Dhib-Jalbut, S. S. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.11.017 · Cited by 45
Self-citationType 1 Interferons Cool the Inflamed Brain
Axtell, R. C., & Steinman, L. (2008) · Immunity · doi:10.1016/j.immuni.2008.04.006 · Cited by 40
Karabudak, R., Kansu, E., Kurne, A., Güç, D., Şengelen, M., & Canpınar, H. (2004) · Journal of Neurology · doi:10.1007/s00415-004-0285-7 · Cited by 38
Airas, L. M., Niemelä, J., Yegutkin, G. G., & Jalkanen, S. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1423.067 · Cited by 37
BAFF is a Biological Response Marker to IFN-β Treatment in Multiple Sclerosis
Gandhi, K. S., McKay, F. C., Schibeci, S. D., Arthur, J. W., Heard, R. N., Stewart, G. J., & Booth, D. R. (2008) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0007 · Cited by 31
Longo, D. E. M. H., Mirandola, S. R., de Oliveira, E. C., Farias, A. S., Pereira, F. G., Lorand-Metze, I. G. H., Brandão, C. O., Ruocco, H. H., Damasceno, B. P., & dos Santos, L. M. B. (2007) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2007.0018 · Cited by 27
Tempering antigen-presenting cells in multiple sclerosis
Prod’homme, T., & Zamvil, S. S. (2008) · Nature Medicine · doi:10.1038/nm0608-614 · Cited by 14
Vallittu, A.-M., Saraste, M., & Airas, L. M. (2007) · Neurological Research · doi:10.1179/016164107x228633 · Cited by 13
Cited by
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
“The need to control infection while limiting inflammation is especially important in the central nervous system (CNS), which relies heavily on innate antiviral responses because leukocyte trafficking across the BBB is tightly regulated (reviewed in Klein and Hunter, 2017).”
InfluentialMultiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy.
Ghasemi, N., Razavi, S., & Nikzad, E. (2016) · PubMed · doi:10.22074/cellj.2016.4867 · Cited by 685
(1973) · BMJ · doi:10.1136/bmj.2.5863.432 · Cited by 488
Multiple Sclerosis: Pathogenesis and Treatment
Loma, I., & Heyman, R. (2011) · Current Neuropharmacology · doi:10.2174/157015911796557911 · Cited by 350
The Immune Response in Multiple Sclerosis
Rodríguez Murúa, S., Farez, M. F., & Quintana, F. J. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052920-040318 · Cited by 335
Metadata
- Authors
- Dhib-Jalbut, S., & Marks, S.
- Venue
- Neurology
- Published
- 2010-01-05
- Volume
- 74
- Issue
- 1_supplement_1
- Pages
- S17-24
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2124720965
- Cited by
- 298
- References
- 47
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.